|
|
|
| Effect of probucol combined with edaravone on hemodynamics and neurological function in patients with cerebral ischemic stroke |
| LIANG Zhuanshuan, LIU Xiangyong, WANG Dan |
| |
|
|
|
| Guide |
|
|
Abstract Objective To explore the efficacy of probucol combined with edaravone in patients with cerebral ischemic stroke (CIS), and the influence on their hemodynamics and neurological function. Methods We retrospectively selected 82 CIS patients as research subjects; they were divided into control group and observation group according to different therapeutic regimens, each with 41 cases. The control group was treated with edaravone while the observation group was treated with edaravone plus probucol. Patients of the two groups were continuously treated for 14 days. The clinical efficacy, National Institute of Health stroke scale (NIHSS) score, modified Barthel index (mBI), mini-mental state examination (MMSE) score, the average velocity (Vm), difference in symmetry of peak flow velocity (DVp), difference in symmetry of average flow velocity (DVm) and peak flow rate (Vp) of the middle cerebral artery, serum Occludin, high sensitivity C reactive protein (hs-CRP), matrix metalloproteinase (MMP)-9 and omentin-1, and the occurrence of adverse reactions were compared between the two groups. Results The total effective rate of the observation group was higher than that of the control group after treatment (92.68% vs. 75.61%，P＜0.05). The mBI and MMSE scores of the observation group were higher than those of the control group after treatment while NIHSS score was lower (P＜0.01); the Vm and Vp of the middle cerebral artery, and omentin-1 level were all higher than those of the control group while DVp, DVm, and serum Occludin, hs-CRP and MMP-9 levels were all lower than those of the control group (P＜0.05). The incidence of adverse reactions did not vary significantly between the two groups (P＞0.05). Conclusion Probucol combined with edaravone shows definite efficacy on CIS, which improves patients cerebral hemodynamics, inhibits inflammatory reaction, and relieves neural dysfunction with high safety.
|
|
|
| Fund: |
|
|
|
|
|
|
